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Abstract
A panel of physicians from the Society for Academic Emergency Medicine (SAEM) Graduate Medical
Education (GME), Ethics, and Industry Relations Committees were asked by the SAEM Board of Direc-
tors to write a position paper on the relationship of emergency medicine (EM) GME with industry.
Using multiple sources as references, the team derived a set of guidelines that all EM GME training pro-
grams can use when interacting with industry representatives. In addition, the team used a question–
answer format to provide educators and residents with a practical approach to these interactions. The
SAEM Board of Directors endorsed the guidelines in June 2009.
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P harmaceutical, biologic, and device manufactur-ers (industry) have been involved with graduatemedical education (GME) for many years in a
variety of forms, including disseminating information
regarding drugs and devices, providing educational
materials, sponsoring continuing medical education
(CME) and speaker programs, funding travel to educa-
tional programs, and funding research, among others.
Physicians and industry share a common goal of provid-
ing the best possible care for their patients. However,
industry has the added responsibility of promoting their
own products in an effort to maximize their returns on
investment and thereby please share holders. This diver-
gence in goals has the potential to create a conflict of
interest or values.1,2
Industry invests billions of dollars annually to dis-
cover new medications.3 To remain financially viable,
they must sell their products to realize a return on
investment. To accomplish this goal they must promote
their products, and they do so through the aforemen-
tioned means. This establishes the relationship with
physicians and GME programs. In 2000, the pharma-
ceutical industry spent nearly $8 billion on product pro-
motion and marketing in the first 6 months of the
year.4 These billions of dollars equate to $8,000 to
$13,000 being spent directly or indirectly on each phy-
sician per year.5,6 Physicians frequently are not fully
aware of the influence promotional activity has on their
medical decision-making.7,8
At the heart of the matter is the notion that physicians
must act ethically, responsibly, and professionally at all
times to care for and protect their patients.9 Students
and residents frequently have their first interaction with
industry representatives at their educational institutions.
Professionalism is deeply influenced by their experiences
at these institutions, as well as what they are taught by
their faculty.10 It has been shown that pharmaceutical
industry influence potentially jeopardizes the profession-
alism of physicians and the institutions that sponsor their
educational programs.11,12
The issue of proper interaction of industry with phy-
sicians, medical organizations, medical schools, spon-
sors of CME, and GME became an important topic
earlier this decade. In an effort to provide direction for
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GME and physicians, a number of professional organi-
zations, including the pharmaceutical industry, created
guidelines regarding the interactions. Notable among
these guidelines were the following:
• ‘‘Gifts to Physicians From Industry’’—American Med-
ical Association (AMA) Code of Medical Ethics
(2001);13
• ‘‘Physicians and the Pharmaceutical Industry’’—Amer-
ican College of Physicians–American Society of Inter-
nal Medicine (ACP-ASIM; 2002);14,15
• ‘‘Physicians and the Pharmaceutical Industry’’—Cana-
dian Medical Association (2002);16
• ‘‘Standards for Commercial Support’’—Accreditation
Council for Graduate Medical Education (ACGME;
2001);17
• Association of American Medical Colleges (AAMC)
Task Force on Financial Conflict of Interest in
Research Statement;18
• Pharmaceutical Research and Manufacturers of Amer-
ica (PhRMA) ‘‘Code on Interactions with Healthcare
Professionals’’ (2002);19 and
• ACGME ‘‘Principles to Guide the Relationship
Between GME and Industry’’ (2002).20
Shortly thereafter, the Council of Emergency Medi-
cine Residency Directors (CORD) Board of Directors
issued a position paper endorsing the ACGME guide-
lines.21 In 2007, the Society for Academic Emergency
Medicine (SAEM) issued a position paper on the ethical
relationships with the biomedical industry.22 Over the
past several years, there has been intense interest and
scrutiny placed on physicians and industry, especially
by the public, who generally feel that pharmaceutical
industries should be regulated more stringently.23 This
resulted in the ‘‘Report of the American Association of
Medical Colleges (AAMC) Task Force on Industry
Funding of Medical Education’’ to the AAMC Executive
Council.24 This, along with the AMA Report of the
Council on Ethical and Judicial Affairs (A-08) ‘‘Industry
Support of Professional Education in Medicine,’’25 also
published in 2008, established guidelines specifically
addressing the interactions of academic medical centers
with industry. PhRMA then revised their guidelines in
July 2008,19 and these guidelines took effect January
2009. In addition, the Institute of Medicine (IOM) issued
recommendations regarding conflicts of interest, specif-
ically addressing the relationship of industry with medi-
cal education.26
Given the recent developments and increasing inter-
est in physician and GME relationships with industry,
the SAEM Board of Directors charged the SAEM GME
Committee, with input from the SAEM Industry Rela-
tions Committee and the SAEM Ethics Committee, to
develop a revised set of guidelines for emergency medi-
cine (EM) training programs. What follows is the con-
sensus report on the revised guidelines, and
recommendations regarding commonly asked questions
(available in Data Supplement S1, available as support-
ing information in the online version of this paper) as
they apply to these guidelines. These guidelines are
derived, copied, and or edited ⁄ adapted from the afore-
mentioned sources.13–26
GUIDELINES FOR BIOINDUSTRY INTERACTION
WITH GME
1. Emergency medicine GME programs should adopt
and implement policies that address specific interac-
tions between academic medical personnel and indus-
try. These policies should reinforce and uphold
institutional and individual efforts to promote a learn-
ing environment that supports professionalism and
eliminates activities that undermine this objective.
2. Emergency medicine GME programs should make
clear to their faculty, students, and staff that to the
extent certain interactions with industry are pro-
hibited within their primary academic medical cen-
ter, they are also prohibited at secondary or off-site
rotations.
a. Emergency medicine GME programs should
communicate to secondary training facilities
their expectations that the off-site venues will
adhere to the standards of the primary site
regarding interaction with industry.
b. Industry should not invite program personnel to
participate in practices prohibited at the primary
site.
3. Emergency medicine GME programs should estab-
lish and implement policies that prohibit the accep-
tance of any gifts, including food, from industry by
physicians and other faculty, staff, student, and
trainees, whether at the primary or at the second-
ary venues. These gifts include gifts from equip-
ment and service providers, as well as
pharmaceutical and device providers.
a. Distribution of medications to EM training pro-
grams, including samples (if permitted), should
be centrally managed in a manner that ensures
timely patient access to optimal therapeutics
throughout the health care system. Physicians
must avoid distribution of misleading or coer-
cive information.
4. Access by industry representatives to individual
physicians, if permitted, should be restricted to pri-
vate, nonpatient care areas and only by appoint-
ment or invitation of the physician.
a. Involvement of students and trainees in such
one-on-one industry-related meetings should
occur only for educational purposes and only
under the supervision of a faculty member.
5. Emergency medicine GME programs should
develop mechanisms whereby industry representa-
tives who wish to provide educational information
on their products may do so by invitation in fac-
ulty-supervised structured group settings that pro-
vide the opportunity of interaction and critical
evaluation. Highly trained industry representatives
with MD, DO, PhD, or PharmD degrees are best
suited for transmitting such scientific information
in these settings.
6. Emergency medicine GME programs sponsoring
CME programs should develop audit mechanisms
that assure compliance with the Accreditation
Council for Continuing Medical Education
(ACCME) regulations and policies.
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7. Medical centers that sponsor GME programs
should establish a central CME office through
which all requests for industry support and receipt
of funds for CME activity are coordinated and
overseen.
8. All educational programs with any support should
be offered only by ACCME accredited providers
according to ACGME standards.
a. Bioindustry funding for education should be in
the form of unrestricted educational grants.
b. Industry support of educational events must be
acknowledged at the time of the presentation or
listed in the event brochure credits and must
formally note compliance with the ACCME Task
Force recommendations.17,27
c. Educational information should be fair, impar-
tial, and accurate. All presenters must disclose
and resolve any financial relationships before
presentation.
d. Presentations should use generic nomenclature
of pharmaceutical products. Therapy compari-
sons should be balanced and represent the spec-
trum of available agents.
9. With the exception of settings in which academic
investigators are presenting results of their indus-
try-sponsored studies to peers and there is
opportunity for critical exchange, EM GME pro-
grams should strongly discourage participation by
their faculty in industry-sponsored speaker’s
bureaus.
10. If EM GME programs allow faculty participation in
industry-sponsored, Food and Drug Administra-
tion–regulated programs, they should develop stan-
dards that define appropriate and acceptable
involvement.
a. Require full transparency and disclosure.
b. Require that payments to personnel be only at
fair market price.
11. Emergency medicine GME programs should pro-
hibit faculty, students, and trainees from:
a. Attending non–ACCME-accredited industry
events billed as CME.
b. Accepting payment for attendance at industry-
sponsored meetings.
c. Accepting personal gifts from industry at such
events.
12. Emergency medicine GME programs should estab-
lish and implement policies requiring that:
a. All scholarships or other educational funds from
industry be given centrally to administration.
b. No quid pro quo be involved in any way.
c. Evaluation and selection of the recipient of such
funds must be the sole responsibility of the med-
ical center administration or of the nonprofit
granting entity, with no involvement by the
donor industry.
d. With the exception of food provided in connec-
tion with ACCME-accredited programming and
in compliance with ACCME guidelines, EM
GME programs should establish and implement
policies stating that industry-supplied food and
meals are considered personal gifts and will not
be permitted or accepted within academic medi-
cal centers.
e. This should also apply to all secondary training
venues.
13. Emergency medicine GME programs should pro-
hibit their physicians, trainees, and students from
directly accepting travel funds from industry, other
than for legitimate reimbursement or contractual
services.
14. Emergency medicine GME programs may allow
industry representatives to provide technical train-
ing when new diagnostic or therapeutic devices
and techniques are introduced. Once expertise in
the use of previously new devices has developed
within the professional community, continuing
industry involvement in educating practitioners is
no longer warranted.
15. Emergency medicine GME programs should assist
medical schools and teaching hospitals to design cur-
riculum standards and teaching material for all
phases of medical education, from medical school to
CME, that provide tools to educate students, resi-
dents, and faculty about the processes and disciplines
of drug discovery, development, clinical testing,
safety, therapeutics, and regulation. Residency
programs and medical schools should teach recogni-
tion, evaluation, and other critical thinking skills
to develop a sense of evaluation among students.
This education module should include all aspects
delineated in the ACGME ‘‘Principles to Guide the
Relationships between GME and Industry.’’20
16. Emergency medicine GME programs should assist
in developing optimal information systems, includ-
ing Web-based technologies, for disseminating
information on new products.
This comprehensive list of guidelines should assist all
EM program directors and department chairs by pro-
viding the guidance needed when interacting with
industry. It has been noted that there is much variability
among EM programs with regard to their relationship
with industry.28 These guidelines will, hopefully, help to
eliminate some of this variability.
DISCUSSION
The relationship between industry and GME and phy-
sician-related education and research is undeniable.
The IOM Committee supports further restrictions, but
recognizes that ‘‘a goal of $0 contributions from indus-
try’’ is not likely.29,30 Given the financial constraints
for many GME programs, it is likely industry will play
as big, if not a bigger, role in the future. Industry has
provided funding to support residency positions in at
least one specialty to date.31 There is growing concern
that medicine’s increasing reliance on industry finan-
cial support of professional education has undermined
its status in society.32 Commercial support of provid-
ers accredited by the ACCME increased by a factor of
300% from 1998 to 2006, to $1.2 billion.33 In addition,
this support accounts for approximately half of all the
income to nationally accredited CME providers. A
2006 survey of department chairs revealed 25%
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reported their departments accepted financial support
for residency or fellowship training, 38% accepted
food and beverages, and 22% accepted financial sup-
port for travel and meetings.34 Physicians often do not
recognize the financial educational support.20 GME
programs are potentially effective venues for industry
marketing and promotion given the educational envi-
ronment.20,35
Physicians and residents frequently do not recognize
the influence that industry gifts and services have on
them.36 Several studies have shown that physicians
deny industry’s influence.5,37–43 However, research
shows a strong correlation between receiving industry
benefits and favoring their products.7,8,44 Physicians
and residents feel they are immune to the promotional
activities.45 Sierles et al.46 reported that students felt
that they were entitled to industry gifts and that spon-
sored educational events were likely to be biased, but
helpful. They also observed that students manifested
the same behavior as residents, such as accepting gifts
while disapproving of them. Although physicians feel
immune, the patients perceive industry gifts as inappro-
priate or influential on medical practice.37,47,48
Given that industry is likely to continue to have some
interaction and relationship with GME, it is critical not
only to develop guidelines, but also to develop educa-
tional curricula addressing the interaction as well as
developing independent, unbiased sources of informa-
tion on new drugs and devices. Examples of centralized
information sources include peer-reviewed journals,
FDA medical reviewers’ summary reports on new drug
applications that are approved, and information used
for submission to regulatory authorities.24 Carroll et
al.49 reported that educational interventions can
increase skepticism toward industry marketing tech-
niques and influence intentions and behavior of trainees
with respect to their relationships with industry repre-
sentatives, at least in the short term. All of the afore-
mentioned guidelines allude to the need for GME
programs and faculty within them to develop educa-
tional programs and to act as role models.
CONCLUSIONS
Emergency medicine GME programs are likely to have
some interactions with industry representatives. Pro-
gram faculty must act as responsible role models.
SAEM has developed guidelines to help program direc-
tors deal with issues that may arise when dealing with
industry and provide some level of consistency within
the specialty. In addition, GME programs have the
added responsibility of educating residents and stu-
dents on the ethical and professional responsibilities of
their trainees when interacting with industry.
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SUPPORTING INFORMATION
The following supporting information is available in the
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Data Supplement S1. Frequently asked questions.
The document is in PDF format.
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for the content or functionality of any supporting infor-
mation supplied by the authors. Any queries (other than
missing material) should be directed to the correspond-
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APPENDIX A
SAEM Graduate Medical Education Committee
Chair: Jacob Ufberg, MD
Board: Liaison O. John Ma, MD
Members Kelly Barringer, MD, Suzanne Bentley, MD,
Louis Binder, MD, Christopher Carpenter, MD, Jennifer
Casaletto, MD, Douglas Char, MD, Lamont Clay, MD,
Jonathan Davis, MD, Jeffrey Druck, MD, Myto Duong,
MD, Michael Epter, MD, Susan Farrell, MD, Manish
Garg, MD, Scott Goldstein, MD, Veronica Greer, MD,
Alisa Hayes, MD, Armando Hevia, MD, David Howes,
MD, Sean Kelly, MD, Chad Kessler, MD, Barbara
Killian, MD, Terry Kowalenko, MD, Ian Martin, MD,
Christopher McDowell, MD, Anne Messman, MD, Tho-
mas Noeller, MD, Thomas Payton, MD, Tyson Pillow,
MD, Chet Schrader, MD, Shellyann Sharpe, MD
SAEM Ethics Committee
Chair: Jeremy Simon, MD, PhD
Board: Liaison Cherri Hobgood, MD
Members Shellie Asher, MD, Christopher Brooks,
MD, Venkata Feeser, MD, Alisa Hayes, MD, Eric Isaacs,
MD, Kenneth Iserson, MD, John Jesus, MD, Jacob
Keeperman, MD, Sangeeta Lamba, MD, Gregory
Larkin, MD, David Lu, MD, MBE, Priya Mammen, MD,
Catherine Marco, MD, John Marshall, MD, Elizabeth
Nestor, MD, Aasim Padela, MD, Tammie Quest, MD,
Raquel Schears, MD, MPH
SAEM Industry Relations Committee
Chair: Robert Birkhahn, MD
Board: Liaison Deborah Diercks, MD
Members Bruce Becker, MD, MPH, Joseph Becker,
MD, Andra Blomkalns, MD, Benjamin Friedman, MD,
Joshua Goldstein, MD, Edward Jauch, MD, Howard
Klausner, MD, David Kramer, MD, Todd Larabee, MD,
Richard Nowak, MD, Ali Raja, MD, Jeffrey Sankoff,
MD, Nathan Shapiro, MD, Richard Summers, MD, Jim
Weber, DO
1030 Kowalenko et al. • INDUSTRY RELATIONS WITH EM GME PROGRAMS
